Deferiprone to delay dementia (the 3D trial)

Abstract

AbstractBackgroundPotential therapeutic targets for Alzheimer’s disease (AD) outside of β‐amyloid are of increased interest. Brain iron has been reported to predict accelerated AD progression when measured using fluid biomarkers (CSF ferritin), quantitative susceptibility mapping MRI, or directly in post‐mortem tissue, and is one potential therapeutic target. Brain iron may contribute to neurodegeneration by becoming pro‐oxidant (e.g. ferroptosis), or by promoting an inflammatory phenotype of microglia. Deferiprone is an orally bioavailable, BBB‐penetrant moderate iron chelating drug approved for the peripheral iron overload in β‐thalassemia. Deferiprone reported promising evidence for disea..